Brokers Set Expectations for Eyenovia Inc’s Q1 2019 Earnings (EYEN)

Eyenovia Inc (NASDAQ:EYEN) – Analysts at Oppenheimer issued their Q1 2019 earnings per share (EPS) estimates for Eyenovia in a research note issued on Wednesday, April 24th. Oppenheimer analyst E. Rajavelu forecasts that the company will earn ($0.61) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $9.00 target price on the stock. Oppenheimer also issued estimates for Eyenovia’s Q2 2019 earnings at ($0.61) EPS, Q3 2019 earnings at ($0.43) EPS, Q4 2019 earnings at ($0.43) EPS, FY2019 earnings at ($2.09) EPS, FY2020 earnings at ($1.13) EPS, FY2021 earnings at ($0.40) EPS and FY2022 earnings at $0.45 EPS.

Eyenovia (NASDAQ:EYEN) last issued its quarterly earnings results on Wednesday, March 27th. The company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.17).

EYEN has been the topic of several other research reports. HC Wainwright set a $14.00 target price on Eyenovia and gave the company a “buy” rating in a research note on Tuesday, February 26th. Zacks Investment Research cut Eyenovia from a “hold” rating to a “sell” rating in a research note on Tuesday, February 26th. Finally, ValuEngine cut Eyenovia from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd.

Shares of EYEN opened at $6.64 on Monday. The stock has a market capitalization of $79.81 million, a P/E ratio of -3.65 and a beta of 1.82. Eyenovia has a 1-year low of $2.40 and a 1-year high of $9.00.

A number of large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp purchased a new position in Eyenovia during the 4th quarter valued at about $36,000. Vanguard Group Inc purchased a new position in Eyenovia during the 3rd quarter valued at about $157,000. Finally, Vanguard Group Inc. purchased a new position in Eyenovia during the 3rd quarter valued at about $157,000. 9.17% of the stock is currently owned by institutional investors.

Eyenovia Company Profile

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

Recommended Story: What is the QQQ ETF?

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.